by thaan thaan | Oct 31, 2024
François Beaubien, Ph.D., C.F.A., joined Sectoral in 2014 and now serves as a Partner on the NEMO team. He is primarily responsible for managing deal flow and conducting in depth due diligence on private biotech companies. François is a director on the board of...
by thaan thaan | Oct 31, 2024
Derek DiRocco is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Mineralys, Werewolf Therapeutics, Acrivon Therapeutics, Rivus Pharmaceuticals, IDRx, Evommune, Forward Therapeutics, and...
by thaan thaan | Jul 11, 2024
Yuexin is Director at Andera Partners. He has been involved in life sciences portfolio companies including Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED and JenaValve. Before...
by evommune | Dec 5, 2023
Felice Verduyn-van Weegen is a Partner at EQT. Felice worked for LSP from 2015 until 2022, when LSP joined forces with EQT and became EQT Life Sciences. Prior to joining LSP, Felice worked as a Consultant at McKinsey & Company in Amsterdam. Prior to working at...
by evommune | Dec 5, 2023
Dr. Benjamin F. McGraw is Executive Chairman of Perfuse Therapeutics, a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. He is also a Director at TheraVida, a private pharmaceutical company focused on therapies for...
